Cancer reports (Hoboken, N.J.) · 2025
Chemotherapy-Induced Peripheral Polyneuropathy in Pediatric Acute Lymphoblastic Leukemia: A Case Report on Manifestation, Management, and Outcome.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Mattar Eman, Al Sharidah Sondus, Hashem Omnia A
Аннотация
BACKGROUND: Chemotherapy-induced peripheral polyneuropathy (CIPN) is a debilitating side effect of cancer treatment such as in acute lymphoblastic leukemia (ALL). Characterized by the dysfunction of the peripheral nervous system, CIPN can occur in 90% of pediatric patients, significantly impairing their quality of life. In most cases, it necessitates the modification of standard chemotherapy regimens, which can compromise the treatment efficacy and increase the risk of relapse.
CASE: We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.
CONCLUSIONS: Early recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.
CASE: We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.
CONCLUSIONS: Early recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.